Risk factors, stroke rates and aspirin prescribing trends in the Canadian Fabry disease initiative cohort.

ABSTRACT:

Background

Fabry disease (FD) is an X-linked disorder caused by deleterious variants in GLA. Cardiovascular disease (CVD) causes premature mortality in FD. Hope for aspirin (acetylsalicylic acid, ASA) to reduce CVD risks in FD as primary prevention may have been tempered by the 2018 ARRIVE, ASCEND, and ASPREE clinical trials. It is unclear how new ASA guidance applies to FD patients, who have a high rate of young-onset, small vessel stroke compared with the general population.

Methods

Longitudinal data spanning 2007-2023 from patients in the Canadian Fabry Disease Initiative (CFDI) were analyzed retrospectively. Incident stroke and transient ischemic attack (TIA), other CVD events, FD-specific risk factors, and ASA/antiplatelet ("ASA/AP") prescription before and after 2018 w

SUBMITTER: Theberge ET 

PROVIDER: S-EPMC12595872 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature